Gery P Guy1, Steven R Machlin2, Donatus U Ekwueme3, K Robin Yabroff4. 1. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, Georgia. Electronic address: irm2@cdc.gov. 2. Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, Rockville. 3. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, Georgia. 4. Division of Cancer Control and Population Sciences (Yabroff), National Cancer Institute, Rockville, Maryland.
Abstract
BACKGROUND: Skin cancer, the most common cancer in the U.S., is a major public health problem. The incidence of nonmelanoma and melanoma skin cancer is increasing; however, little is known about the economic burden of treatment. PURPOSE: To examine trends in the treated prevalence and treatment costs of nonmelanoma and melanoma skin cancers. METHODS: This study used data on adults from the 2002-2011 Medical Expenditure Panel Survey full-year consolidated files and information from corresponding medical conditions and medical event files to estimate the treated prevalence and treatment cost of nonmelanoma skin cancer, melanoma skin cancer, and all other cancer sites. Analyses were conducted in January 2014. RESULTS: The average annual number of adults treated for skin cancer increased from 3.4 million in 2002-2006 to 4.9 million in 2007-2011 (p<0.001). During this period, the average annual total cost for skin cancer increased from $3.6 billion to $8.1 billion (p=0.001), representing an increase of 126.2%, while the average annual total cost for all other cancers increased by 25.1%. During 2007-2011, nearly 5 million adults were treated for skin cancer annually, with average treatment costs of $8.1 billion each year. CONCLUSIONS: These findings demonstrate that the health and economic burden of skin cancer treatment is substantial and increasing. Such findings highlight the importance of skin cancer prevention efforts, which may result in future savings to the healthcare system. Published by Elsevier Inc.
BACKGROUND:Skin cancer, the most common cancer in the U.S., is a major public health problem. The incidence of nonmelanoma and melanoma skin cancer is increasing; however, little is known about the economic burden of treatment. PURPOSE: To examine trends in the treated prevalence and treatment costs of nonmelanoma and melanoma skin cancers. METHODS: This study used data on adults from the 2002-2011 Medical Expenditure Panel Survey full-year consolidated files and information from corresponding medical conditions and medical event files to estimate the treated prevalence and treatment cost of nonmelanoma skin cancer, melanoma skin cancer, and all other cancer sites. Analyses were conducted in January 2014. RESULTS: The average annual number of adults treated for skin cancer increased from 3.4 million in 2002-2006 to 4.9 million in 2007-2011 (p<0.001). During this period, the average annual total cost for skin cancer increased from $3.6 billion to $8.1 billion (p=0.001), representing an increase of 126.2%, while the average annual total cost for all other cancers increased by 25.1%. During 2007-2011, nearly 5 million adults were treated for skin cancer annually, with average treatment costs of $8.1 billion each year. CONCLUSIONS: These findings demonstrate that the health and economic burden of skin cancer treatment is substantial and increasing. Such findings highlight the importance of skin cancer prevention efforts, which may result in future savings to the healthcare system. Published by Elsevier Inc.
Authors: Howard W Rogers; Martin A Weinstock; Ashlynne R Harris; Michael R Hinckley; Steven R Feldman; Alan B Fleischer; Brett M Coldiron Journal: Arch Dermatol Date: 2010-03
Authors: Jessica W Kyle; James K Hammitt; Henry W Lim; Alan C Geller; Luke H Hall-Jordan; Edward W Maibach; Edward C De Fabo; Mark C Wagner Journal: Pediatrics Date: 2008-05 Impact factor: 7.124
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: Niels Kvorning Ternov; T Vestergaard; L Rosenkrantz Hölmich; K Karmisholt; A L Wagenblast; H Klyver; M Hald; L Schøllhammer; L Konge; A H Chakera Journal: Arch Dermatol Res Date: 2020-06-28 Impact factor: 3.017
Authors: Eman A Alshaikh; Abdulaziz F Almedimigh; Abdulmajeed M Alruwaili; Abdullah H Almajnoni; Ali Alhajiahmed; Thamer S Almalki; Sukayna Z Alfaraj; Jesse M Pines Journal: J Cancer Educ Date: 2019-08 Impact factor: 2.037
Authors: Anthony M Rossi; Joseph Sobanko; Naomi Lawrence; Jeremy Bordeaux; Todd Cartee; Eric S Armbrecht; Anit Behera; Christian L Baum; Murad Alam; Ian A Maher Journal: Dermatol Surg Date: 2019-07 Impact factor: 3.398
Authors: Nikhil Tyagi; Sanjeev K Srivastava; Sumit Arora; Yousef Omar; Zohaib Mohammad Ijaz; Ahmed Al-Ghadhban; Sachin K Deshmukh; James E Carter; Ajay P Singh; Seema Singh Journal: Cancer Lett Date: 2016-09-28 Impact factor: 8.679
Authors: Dawn M Holman; Helen Ding; Gery P Guy; Meg Watson; Anne M Hartman; Frank M Perna Journal: JAMA Dermatol Date: 2018-05-01 Impact factor: 10.282